

## THE EFFECT OF DRUG-ELUTING STENTS ON CLINICAL AND ANGIOGRAPHIC OUTCOMES IN RENAL FAILURE PATIENTS WITH DIALYSIS: MULTICENTER REGISTRY IN ASIA

i2 Poster Contributions

Georgia World Congress Center, Hall B5

Monday, March 15, 2010, 3:30 p.m.-4:30 p.m.

Session Title: Pharmacotherapies and Complex Patients

Abstract Category: PCI - Renal Insufficiency

Presentation Number: 2504-508

Authors: *Sunao Nakamura, Hisao Ogawa, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan Udayachalerm, Damras Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, Chiba, Japan*

**Background:** Patients treated with renal failure have been reported having high incidence of mortality and other complications rate after PCI. Optimal treatment of PCI for renal failure patients with dialysis is still unknown. Aim: The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES), BiolimusA9 (BES) and Everolimus-eluting stent (EES) on the outcome of percutaneous coronary intervention in renal failure patients with dialysis (CRF-HD).

**Methods:** A prospective analysis of 762 patients with CRF-HD (258 SES, 210 PES, 108 ZES, 88 BES, 98 EES) in six high volume Asian centers after successful stenting was performed. The study endpoints were major adverse cardiac events (MACE) at 30 days, 12 months and restenosis rate and target lesion revascularization (TLR) at 12 months.

**Results:** The baseline clinical characteristics between 5 groups were similar. See table for clinical results.

**Conclusion:** The use of drug-eluting stents in patient with CRF-HD was safe with low acute complication. Patients treated with PES showed lesser incidence of MACE at 12 months and lower rate of restenosis compared with other drug-eluting stents.

	SES	PES	ZES	BES	EES
Number of patients	258	210	108	88	98
Multivessel disease (%)	89.1	89.5	87.0	88.6	91.2
MACE at 30 days (%)	0.8	1.0	0.9	1.1	0
MACE at 12 months (%)	16.7	10.5*	21.2	21.5	19.4
Reference diameter (mean: mm)	2.80	2.78	2.82	2.84	2.90
Lesion type: % of B2, C (%)	64.0	66.7	53.7	70.4	69.4
Stent length (mean: mm)	28.8	29.4	26.3	29.3	25.8
Minimum lumen diameter post procedure (mean: mm)	2.65	2.60	2.58	2.59	2.60
Minimum lumen diameter at 12 months (mean: mm)	2.14	2.38*	2.08	2.05	2.22
Restenosis rate at 12 months (%)	17.4	9.5*	22.2	20.4	20.4
TLR at 12 months (%)	15.1	9.5*	20.3	20.4	19.4
*p<0.05 vs. others					